Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 May 15;23(7):573-6.
doi: 10.1016/s0828-282x(07)70803-6.

More medications, fewer pills: combination medications for the treatment of hypertension

Richard Lewanczuk  1 , Sheldon W Tobe
Affiliations
Review

More medications, fewer pills: combination medications for the treatment of hypertension

Richard Lewanczuk et al. Can J Cardiol. .

Abstract
in English, French

Achieving blood pressure targets in hypertension can be challenging. Often, patients require multiple medications to reach these targets. The Canadian Hypertension Education Program has updated its past recommendations to reflect current knowledge regarding effective antihypertensive combinations. Evidence for the use of specific drug combinations in achieving blood pressure targets has been reviewed, and the inventory of effective drug combinations has been expanded. From a clinical perspective, fixed-dose antihypertensive combinations offer certain advantages in terms of efficacy, adherence, cost, convenience, patient-perceived 'wellness' and side effects. Consequently, in the future, fixed-dose combination formulations are likely to become increasingly used in the treatment of cardiovascular disease.

Pour les hypertendus, il peut être difficile de parvenir aux cibles de tension artérielle (TA). Souvent, les patients doivent prendre de multiples médicaments pour y parvenir. Le Programme éducatif canadien sur l’hypertension a mis à jour ses recommandations afin de refléter les connaissances courantes sur les polythérapies antihypertensives efficaces. On a analysé les données probantes sur l’utilisation de polythérapies précises pour obtenir les cibles de TA et accru le nombre de polythérapies efficaces. D’un point de vue clinique, les polythérapies antihypertensives à dose fixe offrent certains avantages en matière d’efficacité, d’observance, de coût, de caractère pratique, de « bien-être » perçu par le patient et d’effets secondaires. Par conséquent, à l’avenir, des formules de polythérapie à dose fixe pourraient être de plus en plus utilisées dans le traitement des maladies cardiovasculaires.

PubMed Disclaimer

References

    1. Joffres MR, Hamet P, MacLean DR, L’Italien GJ, Fodor G. Distribution of blood pressure and hypertension in Canada and the United States. Am J Hypertens. 2001;14:1099–105. - PubMed
    1. Onysko J, Maxwell C, Eliasziw M, Zhang JX, Johansen H, Campbell NR, Canadian Hypertension Education Program Large increases in hypertension diagnosis and treatment in Canada after a healthcare professional education program. Hypertension. 2006;48:853–60. - PubMed
    1. Khan NA, McAlister FA, Rabkin SW, et al. Canadian Hypertension Education Program The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II – therapy. Can J Cardiol. 2006;22:583–93. - PMC - PubMed
    1. Padwal RS, Hemmelgarn BR, McAlister FA, et al. for the Canadian Hypertension Education Program The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I – blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 2007;23:529–38. - PMC - PubMed
    1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 20022882981–97.(Errata in 2003;289:178, 2004;291:2196) - PubMed

MeSH terms

Substances